The Biosimilar Market Access Committee (Biosimilar medicines Group, a Medicines for Europe sector group) undertook a 2023 Biosimilar market review consisting of updates on biosimilar medicines policy across Europe (28 European countries).
The highlights of this overview have been consolidated below and illustrate both key challenges and recommendations on how to improve specific policy interventions (e.g. pricing and reimbursement, procurement, prescribing and dispensing) to enhance biosimilar medicines use and competition in the biologics market in Europe.
Conversations on EU Pharma is back with a third episode we will explore the role played by specialised nurses in delivering positive patient outcomes with biologic therapies and the development of integrated care for patients living with Non-Communicable Diseases (NDC), starting with an overview on the impacts of Covid-19 on the nursing community.
If would like to know more about this topic, you can dive into the resources mentioned during this episode:
Listen to the episode on:
Amazon Music – Apple Podcast – Castbox – Google Podcasts – OverCast – Pocket Casts – RadioPublic – YouTube – Spotify – Stitcher
The second episode of Conversations on EU Pharma will focus on equitable access to medicines for patients and how the path to timely access to treatment can be challenging.
With a focus on Central and Eastern Europe and the consequences of the pandemic on healthcare systems, our host and honourable speakers exchange their views on thoughtful policy reforms to ensure equitable access to medicines for all patients across Europe.
To learn more, consult our report “Removing access barriers in Central and Eastern Europe: How can we ensure equitable access to medicines for all European patients”?
Thank you for listening to us.
Please note that the episode was recorded before the Russia-Ukraine War, which is also impacting many Central and Eastern European countries.
Listen to the episode on:
Amazon Music – Apple Podcast – Castbox – Google Podcasts – OverCast – Pocket Casts – RadioPublic – YouTube – Spotify – Stitcher
In our very first episode, we will talk about Value Added Medicines (VAMs) to understand what benefits they can deliver to patients and the whole healthcare community.
If this episode piques your curiosity, visit the VAMs section on our website for more information.
To learn more about the benefits of VAMs for patients with respiratory diseases, check Monica Fletcher‘s publications and take a look at the Asthma UK Centre for Applied Research and at BREATHE – The Health Data Research Hub for Respiratory Health.
Listen to the episode on:
Amazon Music – Apple Podcast – Castbox – Google Podcasts– Pocket Casts – RadioPublic – YouTube –Spotify – Stitcher